Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prestige 2: Rimegepant in relation to obesity in migraine
2025-521475-31-00Phase 4Authorised
- Sponsor
- Barmherzige Brüder
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rimegepant in migraine (2 arms), sponsored by Barmherzige Brüder. Primary endpoint: 2-hour treatment response. Planned start Mar 2026; status: authorised.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2025-521475-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521475-31-00.